Eisai Innovation

← Back to your selection

Activity in this selectionsbi-us-gateway-fund-93dbcddb

Rounds participated in: 1
Confirmed lead rounds: —
New companies: 1
Funding in participating rounds: $3.7M

By stage

Pre-seed1

By primary sector

Biotech1

By country

United States1

Rounds

1 in this selection

Feb 18

Sift Biosciences

Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases

$3.7MPre-Seed

Role not disclosed